Abemaciclib (EU: Verzenios, U.S.: Verzenio) and fulvestrant for the treatment of advanced breast cancer


Abemaciclib (trade name EU: Verzenios, U.S.: Verzenio) has been approved in Germany since September 2018 for the treatment of advanced hormone-receptor-positive breast cancer in women if the cancer has already spread to other parts of the body or is locally advanced. It is used as a part of antihormonal therapy in combination with an aromatase inhibitor or the anti-estrogen drug fulvestrant.

Breast tumors are surgically removed, if possible. But sometimes the tumor has already become too large or the cancer has spread to other parts of the body (metastasis) through the blood or lymphatic system. This is called advanced breast cancer.

One factor affecting the speed at which breast cancer cells spread is whether they have receptors for such as estrogen or progesterone. If they do, it is called hormone-receptor-positive (HR-positive) cancer. In these tumors, such as estrogen or progesterone accelerate the growth of cancer cells.

A certain protein on the surface of the cancer cells, called the HER2 receptor (human epidermal growth factor receptor 2), also reacts to growth signals and accelerates tumor growth. If there are a smaller number of these receptors on the cells of a breast tumor, it is called HER2-negative breast cancer. HER2-negative breast cancer grows relatively slowly. Abemaciclib isn't an option for women whose cancer cells carry the HER2 receptor (HER2-positive breast cancer).

Abemaciclib inhibits cell division in the cancer cells, slowing down tumor growth.


Abemaciclib is available in the form of tablets, in three different doses: 50, 100 and 150 mg. The recommended dose is 150 mg twice a day.

The dose depends on how well the patient tolerates the drug, as well as on the side effects, and can be adjusted individually.

Other treatments

For women with advanced hormone-receptor-positive and HER2-negative breast cancer, the following standard treatments are available:

First-line antihormonal treatment:

  • Women who have already gone through menopause can use aromatase inhibitors such as anastrozole or letrozole or the anti-estrogen drug fulvestrant, which block hormone production. If these medications can’t be used, tamoxifen is an option.
  • Women who haven’t yet gone through menopause, or who are still going through menopause, can use tamoxifen. Menopause is then also induced with medication.

Subsequent treatment if previous antihormonal treatment was unsuccessful:

  • For women who have already gone through menopause, the options include the drugs tamoxifen, anastrozole, fulvestrant, letrozole, exemestane, or everolimus in combination with exemestane. The choice of drug will depend on previous treatments and the stage of the disease.
  • Women who haven’t yet gone through menopause, or who are still going through menopause, can have a number of additional antihormonal treatments to fight the cancer. This is chosen depending on factors such as which treatments have been tried before. The treatment is individually modified by the doctor.


In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of abemaciclib in combination with fulvestrant compared with the standard treatments for women with advanced hormone-receptor-positive breast cancer. They did two separate assessments: one for treatment with abemaciclib as part of first-line treatment, and one for abemaciclib when used in subsequent treatment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of abemaciclib (EU: Verzenios, U.S.: Verzenio).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Abemaciclib in combination with fulvestrant (breast cancer) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-73. January 30, 2019. (IQWiG reports; Volume 719).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on February 28, 2019
Next planned update: 2022


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.